TAK-117

DRUG5 trials

Sponsors

Millennium Pharmaceuticals, Inc., Avera McKennan Hospital & University Health Center

Conditions

Advanced Nonhematologic MalignanciesAdvanced Solid TumorMetastatic Solid TumorsNeoplasm, Advanced or MetastaticNon-small Cell Lung Cancer

Phase 1

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

CompletedNCT01449370

Millennium Pharmaceuticals, Inc.Metastatic Solid Tumors

Start: 2011-10-31End: 2016-01-31Updated: 2017-03-09

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

CompletedNCT01899053

Millennium Pharmaceuticals, Inc.Advanced Nonhematologic Malignancies

Start: 2013-06-28End: 2018-04-30Updated: 2019-10-30

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

TerminatedNCT02393209

Millennium Pharmaceuticals, Inc.Non-small Cell Lung Cancer

Start: 2015-06-03End: 2017-01-20Updated: 2018-02-07

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

CompletedNCT02625259

Millennium Pharmaceuticals, Inc.Neoplasm, Advanced or Metastatic

Start: 2016-01-08End: 2016-07-22Updated: 2018-01-08

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

CompletedNCT03154294

Avera McKennan Hospital & University Health CenterAdvanced Solid Tumor

Start: 2017-07-06End: 2022-11-20Updated: 2024-07-26

Related Papers

Sapanisertib and serabelisib (PIKTOR) with paclitaxel and a diet substudy in patients with advanced/recurrent endometrial cancer (GOG-3111).

Journal of Clinical Oncology2025-05-28

Serabelisib, sapanisertib (PIKTOR) and paclitaxel: A combinatorial approach to improve PI3K/mTOR/AKT pathway inhibition and treatment response in solid tumors.

Journal of Clinical Oncology2024-06-01

Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.

2022-07-1516 citations

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

Journal of Clinical Oncology2021-05-202 citations

Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

Journal of Clinical Oncology2020-05-209 citations

First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.

Journal of Clinical Oncology2015-05-208 citations

Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models.

Molecular Cancer Therapeutics2013-11-013 citations

Abstract C176: The combination of mTORC1/2 and PI3Kα inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.

Molecular Cancer Therapeutics2013-11-012 citations